CME in Minutes: Education in Oncology & Hematology

Please visit answersincme.com/860/103518989-replay1 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by John Strickler, MD; and Daniel Ahn, DO, MS. In this activity, experts in metastatic colorectal cancer (mCRC) discuss strategies for sequencing later-line therapies and planning treatment pathways to preserve future options. Upon completion of this series, participants should be better able to: Apply evidence-based strategies for later-line treatment selection in mCRC; Integrate proactive management strategies to maintain patients on later-line therapy; and Propose treatment plans based on predictors of durable benefit and real-world evidence.

Please visit answersincme.com/860/102724337-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Charu Aggarwal, MD, MPH, FASCO; and Benjamin Levy, MD, FASCO. In this activity, expert oncologists will engage in a case-based discussion examining how current guidelines and evidence inform the use of frontline immunotherapy-based regimens in the management of metastatic non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Review the latest evidence for IO-based regimens in first-line metastatic NSCLC; Apply evidence-based approaches to select IO-based regimens for first-line metastatic NSCLC, based on patient types; Propose workflows that ensure timely biomarker testing and minimize delays in initiating optimal IO-based therapy; and Outline strategies to manage common and serious AEs associated with preferred first-line IO-based regimens, without losing disease control.

Please visit answersincme.com/UZA860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Anne Lynn S. Chang, MD and Zeynep Eroglu, MD. In this activity, experts in nonmelanoma skin cancer discuss clinical advances for the use of immunotherapy for the management of basal cell carcinoma (BCC). Upon completion of this activity, participants should be better able to: Evaluate current guideline-based recommendations for the use of immunotherapy in the management of basal cell carcinoma (BCC) across various stages of disease; Apply evidence-driven criteria to identify patients with BCC who may be appropriate candidates for immunotherapeutic intervention; and Determine real-world clinical approaches to optimize the benefit-risk profiles of immunotherapy in the management of BC.

Please visit answersincme.com/GXT860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Sarah Donahue, MPH, ANP, AOCNP. In this activity an expert in breast cancer discusses the efficacy and safety of oral SERDs in HR+, HER2- advanced breast cancer. Upon completion of this activity, participants should be better able to: Review the evidence-based use of oral SERDs in the treatment plan for patients with HR+, HER2- advanced breast cancer; Specify the key roles of nurses and NPs in optimizing the overall care for patients with HR+, HER2- advanced breast cancer who are candidates for oral SERDs; and Outline a multidisciplinary treatment plan to maximize the long-term care of patients with HR+, HER2- advanced breast cancer.

Please visit answersincme.com/860/102769007-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Aiwu Ruth He, MD, PhD and Mehmet Akce, MD. In this activity, experts in hepatocellular carcinoma (HCC) discuss how the current and emerging clinical evidence for immune checkpoint inhibitor (ICI)–based regimens can elevate personalized care across disease stages, now and into the future. Upon completion of this activity, participants should be better able to: Evaluate the clinical evidence supporting immune checkpoint inhibitor (ICI)–based regimens for the treatment of hepatocellular carcinoma (HCC) across disease settings; Differentiate available ICI-based combination regimens to inform appropriate frontline treatment selection for patients with unresectable HCC; Apply evidence-based strategies to manage immune-related and regimen-specific toxicities associated with ICI-based regimens in patients with HCC; and Design long-term, personalized treatment plans that integrate patient- and disease-related factors into decision-making for HCC.